<?xml version="1.0" encoding="UTF-8"?><xmi:XMI xmlns:cas="http:///uima/cas.ecore" xmlns:xmi="http://www.omg.org/XMI" xmlns:type="http:///org/apache/uima/trials/type.ecore" xmlns:tcas="http:///uima/tcas.ecore" xmi:version="2.0">
    <cas:NULL xmi:id="0"/>
    <tcas:DocumentAnnotation xmi:id="1" sofa="6" begin="0" end="1677" language="x-unspecified"/>
    <type:ORR xmi:id="13" sofa="6" begin="1140" end="1143"/>
    <type:PFSMean xmi:id="17" sofa="6" begin="1245" end="1246"/>
    <type:OSMean xmi:id="21" sofa="6" begin="1251" end="1260"/>
    <cas:Sofa xmi:id="6" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="The present study evaluated activity and toxicity of modulated doses of&#13;&#10;gemcitabine associated to oxaliplatin in patients with secondary CIRS and with&#13;&#10;locally advanced pancreatic adenocarcinoma (LAPC) and metastatic pancreatic&#13;&#10;adenocarcinoma (MPC). Since January 2006, untreated LAPC and MPC patients have&#13;&#10;been assessed with ADL, IADL, CIRS to modulate chemotherapy dosages according to &#13;&#10;co-morbidity stage. Patiens aged&lt;75 years, co-morbidity stage&#13;&#10;primary/intermediate, or =75 years and co-morbidity stage primary, received&#13;&#10;gemcitabine 1,000 mg/m² as a 10 mg/m²/min infusion on day 1 and oxaliplatin 70&#13;&#10;mg/m² as a 2-h infusion on day 2 every 2 weeks. Patiens aged&lt;75 years,&#13;&#10;co-morbidity stage secondary or =75 years and co-morbidity stage&#13;&#10;intermediate/secondary patients received gemcitabine 800 mg/m². Primary endpoint &#13;&#10;was the overall response rate (ORR). Secondary endpoints were disease control&#13;&#10;rate (DCR), PFS, OS and toxicity. Thirty-one patients were recruited: 26% (8/31) &#13;&#10;LAPC and 74% (23/31) MPC; median age 69 years. Co-morbidity stage&#13;&#10;primary/intermediate, 19; secondary, 12. Twenty-seven valuable patients: ORR 30% &#13;&#10;(CI±0.14); disease control rate 85% (CI±0.18). Median follow-up 13 months: median&#13;&#10;PFS and OS were 6 and 15 months, respectively. Valuable cycles 140. Grade 3/4&#13;&#10;toxicity per patient: leukopenia, 18.5%; neutropenia, 55,5%; thrombocytopenia,&#13;&#10;7.4%; SGOT/SGPT, 7.4%; gamma-GT, 7.4%; fever without neutropenia, 3.7%. Median&#13;&#10;received dose intensity: gemcitabine 400 mg/m2/w; oxaliplatin 35 mg/m2/w.&#13;&#10;Modulation of GemOx chemotherapy according, to CIRS stage in advanced pancreatic &#13;&#10;cancer confirms reported efficacy and tolerability."/>
    <cas:View sofa="6" members="1 13 17 21"/>
</xmi:XMI>
